{"id":"abobont-a","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or bruising"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Muscle weakness"},{"rate":null,"effect":"Ptosis (eyelid drooping)"},{"rate":null,"effect":"Dry mouth"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AboBoNT-A is a recombinant botulinum toxin serotype A produced using a cell-free protein synthesis system. It works by entering motor neurons and cleaving SNAP-25, a protein essential for acetylcholine vesicle release, thereby causing temporary paralysis of targeted muscles. This mechanism is used therapeutically to reduce muscle contractions in various conditions.","oneSentence":"AboBoNT-A is a botulinum neurotoxin type A that blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:42:05.634Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cervical dystonia"},{"name":"Blepharospasm"},{"name":"Hemifacial spasm"},{"name":"Spasticity"},{"name":"Chronic migraine"},{"name":"Glabellar lines (aesthetic indication)"}]},"trialDetails":[{"nctId":"NCT04936542","phase":"PHASE4","title":"A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.","status":"COMPLETED","sponsor":"Ipsen","startDate":"2021-06-23","conditions":"Upper Limb Spasticity","enrollment":464},{"nctId":"NCT06886750","phase":"PHASE4","title":"The Effects of Waning of Botulinum Toxin in the Treatment of Cervical Dystonia","status":"NOT_YET_RECRUITING","sponsor":"Western University, Canada","startDate":"2025-03-30","conditions":"Cervical Dystonia, Primary","enrollment":45},{"nctId":"NCT04050527","phase":"","title":"Study to Assess the Effectiveness of AboBoNT-A Injections for Adult Lower Limb Spasticity in a Real Life Cohort","status":"COMPLETED","sponsor":"Ipsen","startDate":"2019-12-19","conditions":"Adult Lower Limb Spasticity","enrollment":438},{"nctId":"NCT05379413","phase":"","title":"Observational Longitudinal Study on the Outbreak and Management of Stroke Related Spasticity","status":"UNKNOWN","sponsor":"Campus Bio-Medico University","startDate":"2022-06-01","conditions":"Spasticity as Sequela of Stroke","enrollment":960},{"nctId":"NCT04396704","phase":"","title":"A Study to Assess Treatment Outcomes of abobotulinumtoxinA and onabotulinumtoxinA Treatments in Real Life Practice in Toxin-naïve Adult Patients With Limb Spasticity.","status":"COMPLETED","sponsor":"Ipsen","startDate":"2021-01-11","conditions":"Spasticity Related to Any Cause Except Cerebral Palsy","enrollment":114}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":67,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dysport®"],"phase":"marketed","status":"active","brandName":"AboBoNT-A","genericName":"AboBoNT-A","companyName":"Ipsen","companyId":"ipsen","modality":"Biologic","firstApprovalDate":"","aiSummary":"AboBoNT-A is a botulinum neurotoxin type A that blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins. Used for Cervical dystonia, Blepharospasm, Hemifacial spasm.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}